MET and neoplasm: Immunoblot analysis of MKN‐45 subcutaneous tumour lysates demonstrated that foretinib treatment led to a dramatic reduction in phosphorylated c‐Met protein levels and the PI3K/MAPK pathway proteins phospho‐AKT, phospho‐ERK and phospho‐p38.